JP2011530585A - 難聴の治療法 - Google Patents

難聴の治療法 Download PDF

Info

Publication number
JP2011530585A
JP2011530585A JP2011522927A JP2011522927A JP2011530585A JP 2011530585 A JP2011530585 A JP 2011530585A JP 2011522927 A JP2011522927 A JP 2011522927A JP 2011522927 A JP2011522927 A JP 2011522927A JP 2011530585 A JP2011530585 A JP 2011530585A
Authority
JP
Japan
Prior art keywords
noise
adenosine receptor
receptor agonist
exposure
adenosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011522927A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011530585A5 (cg-RX-API-DMAC7.html
Inventor
ヴラジェコヴィック、スルドヤン
ソーン、ピーター、ロウランド
ハウスリー、ゲイリー、デイヴィッド
Original Assignee
オークランド・ユニサーヴィシズ・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オークランド・ユニサーヴィシズ・リミテッド filed Critical オークランド・ユニサーヴィシズ・リミテッド
Publication of JP2011530585A publication Critical patent/JP2011530585A/ja
Publication of JP2011530585A5 publication Critical patent/JP2011530585A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2011522927A 2008-08-11 2009-08-11 難聴の治療法 Withdrawn JP2011530585A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ57046908 2008-08-11
NZ570469 2008-08-11
PCT/NZ2009/000164 WO2010019057A1 (en) 2008-08-11 2009-08-11 The treatment of hearing loss

Publications (2)

Publication Number Publication Date
JP2011530585A true JP2011530585A (ja) 2011-12-22
JP2011530585A5 JP2011530585A5 (cg-RX-API-DMAC7.html) 2012-09-20

Family

ID=41669060

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011522927A Withdrawn JP2011530585A (ja) 2008-08-11 2009-08-11 難聴の治療法

Country Status (8)

Country Link
US (1) US20110207689A1 (cg-RX-API-DMAC7.html)
EP (1) EP2328577A4 (cg-RX-API-DMAC7.html)
JP (1) JP2011530585A (cg-RX-API-DMAC7.html)
CN (1) CN102159209A (cg-RX-API-DMAC7.html)
AU (1) AU2009280369A1 (cg-RX-API-DMAC7.html)
CA (1) CA2733918A1 (cg-RX-API-DMAC7.html)
MX (1) MX2011001551A (cg-RX-API-DMAC7.html)
WO (1) WO2010019057A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6279496B2 (ja) * 2015-01-08 2018-02-14 積水化成品工業株式会社 発泡粒子及び発泡成形体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5248770A (en) * 1984-10-26 1993-09-28 The United States Of America, As Represented By The Department Of Health And Human Services Molecular probes for adenosine receptors
US4968672A (en) * 1987-01-02 1990-11-06 The United States Of America As Represented By The Department Of Health And Human Services Adenosine receptor prodrugs
SE9401499D0 (sv) * 1994-05-02 1994-05-02 Item Dev Ab New method of treatment
WO1997037667A1 (en) * 1996-04-10 1997-10-16 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of an a1 adenosine receptor agonist to treat cerebral ischaemia
US6649621B2 (en) * 1997-12-16 2003-11-18 The United States Of America As Represented By The Secretary Of The Navy Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms
US6177434B1 (en) * 1997-12-16 2001-01-23 The United States Of America As Represented By The Secretary Of The Navy Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms
WO2004096256A1 (en) * 2001-01-23 2004-11-11 The United States Of America, As Represented By The Secretary Of The Navy Methods for preventing and treating loss of balance function due to oxidative stress
WO2009132050A2 (en) * 2008-04-21 2009-10-29 Otonomy, Inc. Auris formulations for treating otic diseases and conditions

Also Published As

Publication number Publication date
CA2733918A1 (en) 2010-02-18
EP2328577A1 (en) 2011-06-08
WO2010019057A1 (en) 2010-02-18
MX2011001551A (es) 2011-03-29
EP2328577A4 (en) 2011-10-19
CN102159209A (zh) 2011-08-17
US20110207689A1 (en) 2011-08-25
AU2009280369A1 (en) 2010-02-18

Similar Documents

Publication Publication Date Title
Pourbakht et al. Ebselen attenuates cochlear damage caused by acoustic trauma
Yamashita et al. Post-exposure treatment attenuates noise-induced hearing loss
Sergi et al. Cisplatin ototoxicity in the guinea pig: vestibular and cochlear damage
Hu et al. R-phenylisopropyladenosine attenuates noise-induced hearing loss in the chinchilla
Shoji et al. Differential protective effects of neurotrophins in the attenuation of noise-induced hair cell loss
Himeno et al. Intra-cochlear administration of dexamethasone attenuates aminoglycoside ototoxicity in the guinea pig
Yamashita et al. Delayed production of free radicals following noise exposure
US9889107B2 (en) Methods and compositions for preventing and treating auditory dysfunctions
US6649621B2 (en) Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms
Tsukasaki et al. Acute changes in cochlear potentials due to cisplatin
KR101429735B1 (ko) 와우각 흥분독성에 의해 유발된 이명의 치료를 위한 nmda 수용체 길항제의 용도
EP3322412B1 (en) Use of amitriptyline for blocking brain hemichannels and method for potentiating its effect in vivo
US20100254907A1 (en) Methods for the treatment of tinnitus induced by cochlear excitotoxicity
Harris et al. Prevention of noise-induced hearing loss with Src-PTK inhibitors
Shafik et al. Effect of intratympanic dexamethasone administration on cisplatin-induced ototoxicity in adult guinea pigs
US10966940B2 (en) Methods for the treatment of tinnitus induced by cochlear excitotoxicity
Manalo et al. Adenosine A2B receptor: A pathogenic factor and a therapeutic target for sensorineural hearing loss
Wong et al. Post exposure administration of A1 adenosine receptor agonists attenuates noise-induced hearing loss
Mom et al. Monitoring of functional changes after transient ischemia in gerbil cochlea
Niu et al. The signal transduction pathway for the dopamine D1 receptor in the guinea-pig cochlea
Bielefeld Protection from noise-induced hearing loss with Src inhibitors
US20110207689A1 (en) The treatment of hearing loss
Bielefeld et al. Protection from impulse noise-induced hearing loss with novel Src-protein tyrosine kinase inhibitors
Öntepeli et al. Audiometry results and TEOAE and DPOAE amplitudes in men taking a phosphodiesterase type 5 inhibitor for erectile dysfunction
US20240294925A1 (en) Method of Treatment for Auditory Dysfunction

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120801

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120801

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20130816

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130816